Study objectives: Some investigators have suggested that lung cancer in young patients has a more aggressive course and a poorer prognosis than lung cancer in older patients. The aim of this study was to determine if the basal characteristics and survival in younger patients with lung cancer undergoing surgical resection differ from those of older patients. Design: Retrospective clinical study. Patients: Of 1,208 consecutive patients who underwent surgery for primary lung cancer between June 1984 and March 2000, we reviewed the medical records of 110 younger patients who were < 50 years of age at the time of surgery and compared them with 1,098 older patients (> 50 years of age). All deaths were included. Results: In the younger patient group, asymptomatic disease and adenocarcinoma was significantly more frequent, the rate of smoking was significantly higher, and the amount of smoking (Brinkman index) was significantly larger. For the 94 younger patients with complete resection, the 5-year survival rate was 61.0%, which was not significantly higher than that for the 923 older patients (57.7%). However, the 53 younger patients with stage I disease (5-year survival of 84.3%) had significantly better survival than older patients with the same condition (71.6%). Survival of patients in stage II or stage III disease was not significantly different. Conclusion: The younger patients had significantly better prognoses, and a statistical difference was shown especially in the early stage, while in the advanced stage the malignancy of the lung cancer itself surpassed the difference in survival.
L
ung cancer is the leading cause of cancer-related mortality in both men and women. Although most cases of lung cancer occur in the sixth through eighth decades of life, 5 to 10% are diagnosed in patients Ͻ 50 years of age. 1 There are characteristic features in young patients with lung cancer that differ from those in older patients with lung cancer: a relatively high incidence of female patients and a high incidence of adenocarcinoma. [2] [3] [4] An impression is widely held that young patients with lung cancer have a poorer prognosis than older patients. Many reports 2-9 have described survival rates in lung cancer patients with respect to age. Various investigators have concluded inferior 2, 5, 6, 8 or equivalent 4, 9 survival for younger compared to older patients, but the results are controversial and confusing. The purpose of this study was to analyze various clinical characteristics and longterm survival in younger patients (Ͻ 50 years of age) treated surgically for lung cancer compared with the older patients during the same period.
Materials and Methods
Between June 1984 and March 2000, 1,412 consecutive patients with non-small cell lung cancer underwent pulmonary resection at our institution, of whom 204 patients with induction therapy were excluded from this analysis. Of these 1,208 patients, 110 patients (9.1%) Ͻ 50 years of age at the time of surgery were studied. Histopathologic diagnosis and staging were carried out according to the new TNM staging system, 10 revised in 1997. In 1,017 patients (94 younger and 923 older patients) with complete resections, lobectomy was by far the most common procedure and was performed in 763 patients (75.0%), including 104 combined sleeve resections of the bronchus. Thirty pneumonectomies (2.9%), including 3 sleeve resections, 176 segmentectomies (17.3%), 45 wedge resections, and 3 bronchial resections, were performed.
In this study, we excluded patients with malignant effusion detected before the operation. Immediately after thoracotomy, the pleural cavity was washed with 20 mL of normal saline solution, and a cytologic examination of the fluid was done. When the report result from the pathologist was positive, we diagnosed the disease as malignant effusion (T4) 11, 12 and changed the complete resection into a simpler procedure.
Hilar and mediastinal lymph node dissections were routinely performed in patients with complete resection. The Brinkman index data 13 (the sum of the number of cigarettes smoked per day multiplied by years of smoking) were recorded for 775 patients (73 younger and 702 older patients; 64.2% of all cases), and there were no differences in missing data between younger and older patients. Carcinoembryonic antigen (CEA) was measured before and 1 month after surgery. The cut-off level for CEA was 5.0 ng/mL.
Data are expressed as the mean Ϯ SE. The 2 test was used to compare differences between proportions. The Student's t test was used for analysis of continuous data. This study was a retrospective analysis, and follow-up data were obtained for all patients. Operative mortality rates imply 30-day postoperative mortality plus intraoperative mortality. Hospital death was defined as all deaths during initial hospital stay. The survival rates were estimated using the Kaplan-Meier method in 94 younger patients and 923 older patients who had complete resection. The log-rank test was used to compare survival rates. A p value Ͻ 0.05 was considered significant. Deaths included those due to cancer, noncancer, and unknown causes.
Results
Of 1,208 lung cancer patients, 110 patients (9.2%) were Ͻ 50 years of age at the time of surgery. Within this group of younger patients, 97 patients (88.2%) were 40 to 49 years of age and only 13 patients (11.8%) were Ͻ 40 years of age.
Overall follow-up duration ranged from 5 to 171 months, with a mean of 41 months. The operative mortality rate was 0.33% (4 of 1,208 patients). These four patients died of hemorrhage, pulmonary infarction, acute myocardial infarction, and brain metastasis, respectively. Hospital deaths accounted for 1.1% (13 of 1,208 patients): interstitial pneumonia (n ϭ 3), pulmonary fibrosis (n ϭ 3), pneumonia (n ϭ 2), acute myocardial infarction (n ϭ 2), respiratory failure (n ϭ 1), pulmonary infarction (n ϭ 1), and brain metastasis (n ϭ 1) after surgery during the same hospitalization period.
The difference in the male-to-female ratio was not significant (NS) between younger and older patients. In the younger patient group, asymptomatic disease and adenocarcinoma was diagnosed significantly more frequently, while squamous cell carcinoma was diagnosed significantly less. The number of smokers was significantly higher and the amount of smoking (Brinkman Index) was significantly larger in younger patients (Fig 1 and Table 1 ). However, there was no significant difference in the frequency of adenocarcinoma histologic subtypes (Table 2) .
For the 94 younger patients in all stages combined with complete resection, the 5-year survival rate was 61.0%, which was not significantly higher than that for the 923 older patients with the same condition (Fig 2) . In the survival of patients with incomplete resection, there was no significant difference between the two groups (Fig 3) . Survival of patients with adenocarcinoma was not significantly different between the younger and the older patients. However, the 53 younger patients with stage I disease had significantly better survival than the 541 older patients (5-year survival of 84.3% vs 71.6%; Fig 4) . These differences remained significant in favor of younger patients even after excluding patients with other causes of death (5-year survival of 86.3% vs 73.5%; Fig 5) . Survival of patients with stage II or stage III disease was not significantly different between the younger and the older patients (Fig 4) . In patients with adenocarcinoma, asymptomatic disease, or incomplete resection, significant differences were not found between the two age groups. Survival was not significantly different between the much younger patients (Ͻ 40 years old) and middle-aged patients (Ն 40 years and Ͻ 50 years old).
Discussion
In this retrospective study of Ͼ 1,200 patients who underwent lung resection over a 16-year period, some differences concerning age were found in tumor presentation and prognosis. In our study, 50 Figure 2 . Actual survival curves of 1,017 patients with complete resection according to age. There was no significant difference between the two groups. years of age was chosen as the cutoff to ensure adequate numbers of younger patients to allow for meaningful statistical analyses. The actual number of patients Ͻ 40 years of age was 13 patients (1.1%), and there was no significant difference in survival between much younger (Ͻ 40 years) and middleaged patients (Ն 40 years and Ͻ 50 years old). However, we had the difficulty in comparing our results with those of previous reports, as the cutoff ages to define "young" were different in each report. [2] [3] [4] 7, 9 In the past decade, adenocarcinoma has surpassed squamous cell carcinoma as the most common histologic subtype of lung cancer. 14 Cigarette consumption was significantly higher in the older than the younger patients partly because they are living longer. This difference in smoking resulted in different histology findings. 14 Younger patients had a significantly higher frequency of the asymptomatic disease. Although de Perrot and colleagues 15 attributed the different proportion of asymptomatic disease to the location of the tumor, this did not hold true in our study, in which tumor location did not significantly differ between the two groups.
Various investigators have concluded inferior, 2,5,6,8 or equivalent 4, 9 survival for younger patients compared to older patients. They compared survival in all stages combined, not stage by stage. Thus, in the present study of a large number of lung cancer patients, we compared the survival within each stage. The morbidity and mortality in the present series were relatively low, mainly due to the infrequency of pneumonectomy; the survival rate was acceptable. We performed lung-saving surgery without affecting prognosis in older and younger patients.
In stage I, younger patients had significantly better prognosis, although this was not significant for all stages. In adjusted (tumor-related) survival, the result was the same. These data are consistent with those from the previous observation of Ramalingam and colleagues. 7 However, the reasons why such age-related differences exist remain obscure.
We observed that the effect of age was present only in the early stage and that in the advanced stage the malignancy of the lung cancer itself erased the difference. Neither was the difference explained by other differences in lung cancer presentation and management. The results were considered to be compatible with the clinical impression that cancers in elderly patients generally grow and progress slower than in young patients. 16 It is also known that the incidence of many types of cancer increases with age, and that occurrences of two or three different malignancies in one individual are not uncommon in the elderly population. 17 In this study, there were no significant differences in the concurrence of different malignancies.
Our findings give further support to the hypothesis that the immunocompetence of younger patients is superior to that of the older patients. Indeed, previous experimental studies [17] [18] [19] demonstrated that the same restraint stress resulted in a more serious influence on the immune cells in old than in young mice. Bohr and Anderson 20 reported that this phenomenon could be attributed to the accumulation of DNA damages and to the attenuation of immunosurveillance with age.
In conclusion, the younger patients had significantly better prognoses, and a statistical difference was shown especially in the early stage, while in the advanced stage there was no significant difference. Throughout the course of this article, we refute the notion that younger patients with lung cancer have a worse prognosis due to more aggressive tumors.
